Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Abiraterone improves outcomes for prostate cancer prior to chemo

Treatment with abiraterone acetate, an androgen biosynthesis inhibitor, may benefit patients with progressive metastatic castration-resistant prostate cancer who have not yet undergone chemotherapy, report researchers.

17 Dec 2012

New technique could help develop more-specific, cell-based immune therapies for cancer

A team led by Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at Memorial Sloan-Kettering Cancer Center, has shown for the first time the effectiveness of a new technique that could allow the development of more-specific, cell-based immune therapies for cancer.

17 Dec 2012

New diagnostic innovations could refine the way doctors detect prostate cancer

Despite the volume of prostate cancer tests and treatments, experts and their patients are continually challenged to predict the disease's course and apply the most appropriate treatment. Now, two new diagnostic innovations – the PCA3 urine test and a more targeted prostate biopsy technique - could refine the way doctors diagnose prostate cancer and, subsequently, the way patients elect to treat it.

15 Dec 2012

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

Bayer HealthCare today announced that the company has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for radium Ra 223 dichloride (radium-223), an investigational compound for the treatment of castration-resistant prostate cancer (CRPC) patients with bone metastases.

15 Dec 2012

New finding likely to fuel cost-benefit debate over cancer care

A study published Thursday in the Journal of the National Cancer Institute concluded that proton-beam therapy provided no long-term benefit over traditional radiation despite far higher costs.

15 Dec 2012

Prostate cancer patients experience minimal relief from side effects following proton radiotherapy

Prostate cancer patients receiving the costly treatment known as proton radiotherapy experienced minimal relief from side effects such as incontinence and erectile dysfunction, compared to patients undergoing a standard radiation treatment called intensity modulated radiotherapy (IMRT), Yale School of Medicine researchers report in the Journal of the National Cancer Institute.

14 Dec 2012

Knocking out PKNP gene is the Achilles' heel of some cancers

Medical researchers at the University of Alberta have discovered that knocking out a particular "partner" gene is the Achilles' heel of some cancers.

14 Dec 2012

EZH2 protein enables advanced prostate cancers to spread without stimulation by male hormones

Scientists at Dana-Farber Cancer Institute have discovered a molecular switch that enables advanced prostate cancers to spread without stimulation by male hormones, which normally are needed to spur the cancer's growth. They say the finding could lead to a new treatment for prostate cancers that are no longer controlled by hormone-blocking drugs.

14 Dec 2012

Massage could ease distress of brain cancer

Massage therapy can significantly reduce distress levels in individuals with brain tumors, indicating its potential use to improve quality of life in this population, report US researchers.

13 Dec 2012

China SFDA approves Veridex’s CellSearch test for women with metastatic breast cancer

Veridex, LLC today announced approval from the China State Food & Drug Administration (SFDA) for the CellSearch circulating tumor cell (CTC) test as an in vitro diagnostic for women with metastatic breast cancer.

13 Dec 2012

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Stand Up To Cancer (SU2C) and the Cancer Research Institute (CRI) announce the formation of a Dream Team project dedicated to cancer immunology - "Immunologic Checkpoint Blockade and Adoptive Cell Transfer in Cancer Therapy."

13 Dec 2012

Hospice use driven by finance rather than patient eligibility

Barriers to hospice care in the USA could be more to do with individual hospices' enrollment policies than with patients’ true eligibility, indicate study findings.

12 Dec 2012

Study identifies KNDy neurons as a likely control switch of hot flushes

Hot flushes affect millions of people, and not just women. Yet, it is still unclear what causes the episodes of temperature discomfort, often accompanied by profuse sweating.

12 Dec 2012

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Ground-breaking research by a UCLA team of physicians and engineers demonstrates that prostate cancer can be diagnosed using image-guided targeted biopsy.

11 Dec 2012

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

Diagnosis of prostate cancer remains imperfect. Current methods of prostate biopsy are limited by over detection of slow-growing tumors and under detection of clinically relevant cancers. Investigators at the University of California-Los Angeles Department of Urology have found that a new technique of targeted biopsy in a clinic setting, using local anesthesia, may improve diagnosis and aid in selecting which patients are suitable for active surveillance and which need focal therapy (noninvasive techniques for destroying small tumors within the prostate).

11 Dec 2012

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

The U.S. Food and Drug Administration today expanded the approved use of Zytiga (abiraterone acetate) to treat men with late-stage (metastatic) castration-resistant prostate cancer prior to receiving chemotherapy.

10 Dec 2012

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication ZYTIGA (abiraterone acetate).

10 Dec 2012

Rehabilitation helps restore erectile function post radical prostatectomy

Results from a study published in BJU International indicate that penile rehabilitation programs can help restore erectile function following nerve-sparing robot-assisted radical prostatectomy.

10 Dec 2012

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Active Biotech and Ipsen today announced that the Phase III clinical trial for tasquinimod, a novel compound for the treatment of prostate cancer, is successfully enrolled with over 1,200 randomized patients as planned in the clinical protocol.

10 Dec 2012

Viewpoints: Considering baby boomers' future burden on Medicare; Holtz-Eakin endorses state exchanges; The value (or not) of mammograms

The Congressional Budget Office projects that if current policies continue, total federal spending will rise to 24 percent of gross domestic product in 2022. [Republicans and Washington deficit hawks'] proposed solution is a cap on government spending.

7 Dec 2012

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

Abiraterone improves outcomes for prostate cancer prior to chemo

New technique could help develop more-specific, cell-based immune therapies for cancer

New diagnostic innovations could refine the way doctors detect prostate cancer

Bayer files radium-223 NDA with FDA for treatment of CRPC patients with bone metastases

New finding likely to fuel cost-benefit debate over cancer care

Prostate cancer patients experience minimal relief from side effects following proton radiotherapy

Knocking out PKNP gene is the Achilles' heel of some cancers

EZH2 protein enables advanced prostate cancers to spread without stimulation by male hormones

Massage could ease distress of brain cancer

China SFDA approves Veridex’s CellSearch test for women with metastatic breast cancer

CRI, SU2C form Cancer Immunology Translational Research Dream Team

Hospice use driven by finance rather than patient eligibility

Study identifies KNDy neurons as a likely control switch of hot flushes

MR-Ultrasound fusion biopsy can diagnose prostate cancer

Magnetic resonance ultrasound fusion biopsy may improve prostate cancer diagnosis

FDA expands approved use of Janssen Biotech’s Zytiga to treat men with mCRPC

Janssen receives FDA approval for ZYTIGA to treat metastatic castration-resistant prostate cancer

Rehabilitation helps restore erectile function post radical prostatectomy

Ipsen, Active Biotech complete enrollment in tasquinimod Phase III trial for prostate cancer

Viewpoints: Considering baby boomers' future burden on Medicare; Holtz-Eakin endorses state exchanges; The value (or not) of mammograms

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Prostate Cancer News and Research

Latest Prostate Cancer News and Research

What to know about prostate cancer eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in